Clinical trial
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
NCT03123250 · PROCEPT BioRobotics, Industry · Completed
Key facts
| NCT number | NCT03123250 |
|---|---|
| Title | Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II |
| Official title | Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II |
| Acronym | WATERII |
| Lead sponsor | PROCEPT BioRobotics, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia (BPH) |
| Intervention type | Device |
| Interventions | Aquablation |
| Enrollment | 101 |
| Start date | Aug 14, 2017 |
| Primary completion | Mar 27, 2018 |
| Completion | Dec 20, 2022 |
| First posted | Apr 21, 2017 |
| Last update posted | Jun 28, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: